5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks

Cephalalgia

Volumn 30, Issue 10, 2010, Pages 1157-1158

  Olesen, Jes ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; LASMIDITAN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN 1F RECEPTOR AGONIST; SEROTONIN AGONIST; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; 4 FLUORO N (3 (1 METHYL 4 PIPERIDINYL) 1H INDOL 5 YL)BENZAMIDE; 4-FLUORO-N-(3-(1-METHYL-4-PIPERIDINYL)-1H-INDOL-5-YL)BENZAMIDE; BENZAMIDE DERIVATIVE; INDOLE DERIVATIVE; SEROTONIN RECEPTOR;

ACUTE DISEASE; BINDING AFFINITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EDITORIAL; HUMAN; IN VITRO STUDY; MIGRAINE; NONHUMAN; RECEPTOR AFFINITY; VASOCONSTRICTION; VASODILATATION; DRUG EFFECT; NOTE; PATHOPHYSIOLOGY;

BENZAMIDES; HUMANS; INDOLES; MIGRAINE DISORDERS; RECEPTORS, SEROTONIN; SEROTONIN RECEPTOR AGONISTS;

EID: 79952108610     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102410377671     Document Type: Editorial

References (8)

1. Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, et al. Preclinical pharmacologic profile of the selective 5-HT1F receptor agonist Lasmiditan. Cephalalgia 2010; 30: doi:10.1177/0333102410370873.
2. Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M, et al. and the European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT1F receptor agonist Lasmiditan-a randomized proof of con-cept trial. Cephalalgia 2010; 30: doi:10.1177/0333102410375512.
3. Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001; 358: 1230-1234. (Pubitemid 33010848)
4. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104-1110. (Pubitemid 38298990)
5. Thomsen LL, Iversen HK, Olesen J. Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura. Cephalalgia 1995; 15: 109-16.
6. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arter-ial responses during migraine headache. Lancet 1990; 336: 837-839.
7. Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 2008; 131: 2192-2200.
8. Ho TW, Ferrari MD, Dodkk DW, Galet V, Kost J, Xiaoyin Fan, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, paral-lel-treatment trial. Lancet 2008; 372: 2115-2123.